Teva
Mega deal: Teva acquires Emalex for approximately $900 million
The Israeli pharmaceutical giant is accelerating its growth strategy and adding to its portfolio a groundbreaking treatment for Tourette syndrome in children.
IATI CEOs Forum meets in Kiryat Gat to discuss multinational industry resilience
Teva honored for gender equality as women reach 43% of senior management in Israel
Teva collaborates on skin disease treatment, releases targets
Teva woes continue amid congressional probe, negative outlook
According to the May lawsuit filed by Connecticut Attorney-General William Tong, Teva significantly raised prices on approximately 112 different generic drugs between July 2013 and January 2015.
What’s ‘down’ with Teva?
Yet, as of late 2018, the company announced it would be laying off 1,700 of its Israel-based workers.
Oklahoma judge approves Teva's $85 million opioid settlement
The case is one of around 2,000 by state and local governments seeking to hold drugmakers responsible for an epidemic in the US.
Teva agreed to pay Oklahoma $85m to settle opioid claims
Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced.
Teva shares tumble as company faces price-fixing lawsuit
The Israeli pharmaceutical company is being sued in the US following an alleged price-fixing conspiracy worth "many billions of dollars."
Teva at the center of a lawsuit for raising drug prices
According to the Bloomberg news agency, more than a dozen present and former executives of leading generic companies have been sued.
Teva's new migraine drug helps contain profit fall
Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.
Grotsky debuts as Teva Naot spokesmodel
The media and television personality Dana Grotsky, who – with Guy Pines – cohosts Good Evening With Guy Pines.
Teva hopes generic EpiPen will sell well in U.S. market
An EpiPen, or epinephrine auto-injector, is a medication used to treat serious allergic reactions in emergencies.
U.S. settles with Teva over keeping generic drugs off market
The agency has said that the deals cost consumers billions annually in higher drug costs.